ATXS
Astria Therapeutics Inc.
$6.18
-$0.35(-5.36%)
70
Overall
--
Value
70
Tech
--
Quality
Market Cap
$376.42M
Volume
235.51K
52W Range
$3.56 - $12.92
Target Price
$29.33
Order:
Income Statement
| Metric | Trend | Chart | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|
| OPERATING EXPENSES | ||||||
| Operating Expenses | $195.0M | $53.5M | $83.0M | $111.6M | ||
| Research & Development | $180.2M | $34.3M | $57.3M | $77.1M | ||
| Research Expense | $180.2M | $34.3M | $57.3M | $77.1M | ||
| Selling, General & Administrative | $14.8M | $19.2M | $25.7M | $34.5M | ||
| General & Administrative Expenses | $14.8M | $19.2M | $25.7M | $34.5M | ||
| Salaries & Wages | -- | -- | $6.3M | $13.0M | ||
| Other Operating Expenses | $700.0K | $800.0K | $600.0K | $1.3M | ||
| OPERATING INCOME | ||||||
| Operating income | $-195.0M | $-53.5M | $-83.0M | $-111.6M | ||
| EBITDA | $-194.9M | $-53.5M | $-72.9M | $-94.3M | ||
| NON-OPERATING ITEMS | ||||||
| Intinc | $122.0K | $1.7M | $10.2M | $17.4M | ||
| Net Non-Operating Interest Income/Expense | $122.0K | $1.7M | $10.2M | $17.4M | ||
| Other Income/Expense | $58.0K | $-55.0K | $62.0K | $62.0K | ||
| Other Special Charges | $-58.0K | $-55.0K | $-62.0K | $-62.0K | ||
| PRE-TAX INCOME | ||||||
| EBIT | $-194.9M | $-53.5M | $-72.9M | $-94.3M | ||
| Pre-Tax Income | $-194.9M | $-51.8M | $-72.9M | $-94.3M | ||
| NET INCOME | ||||||
| Net Income | $-194.9M | $-51.8M | $-72.9M | $-94.3M | ||
| Net Income (Continuing Operations) | $-194.9M | $-51.8M | $-72.9M | $-94.3M | ||
| Net Income (Discontinued Operations) | $-194.9M | $-51.8M | $-72.9M | $-94.3M | ||
| Net Income (Common Stockholders) | $-219.3M | $-51.8M | $-72.9M | $-94.3M | ||
| Normalized Income | $-154.0M | -- | -- | $-93.3M | ||
| TOTALS | ||||||
| Total Expenses | $195.0M | $53.5M | $83.0M | $111.6M | ||
| SHARE & EPS DATA | ||||||
| Average Shares Outstanding | $8.9M | $14.6M | $30.1M | $56.2M | ||
| Average Shares Outstanding (Diluted) | $8.9M | $14.6M | $30.1M | $56.2M | ||
| Shares Outstanding | $56.4M | $56.4M | $54.9M | $56.4M | ||
| Basic EPS | $-24.58 | $-3.55 | $-2.42 | $-1.68 | ||
| Basic EPS (Continuing Operations) | $-24.58 | $-3.55 | $-2.42 | $-1.68 | ||
| Diluted EPS | $-24.58 | $-3.55 | $-2.42 | $-1.68 | ||
| Diluted EPS (Continuing Operations) | $-24.58 | $-3.55 | $-2.42 | $-1.68 | ||
| OTHER METRICS | ||||||
| Accrued Preferred Stock Dividends | $24.4M | -- | -- | -- | ||
| Other Gand A | $14.8M | $19.2M | $25.7M | $34.5M | ||
| Otherunder Preferred Stock Dividend | $24.4M | -- | -- | -- | ||
| Preferred Stock Dividends | $24.4M | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ATXS | $6.18 | -5.4% | 235.51K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Astria Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW